Many clinical researchers are still doing their work behind closed doors. Despite being in the middle of the pandemic, they have tried to keep their trials or tests going remotely and they would want to open again fully. It is not the researchers alone who are eager for the research sites to open. Other stakeholders, including interns, have found themselves in that dilemma.
For instance, in the U.S., the three-phase plan for reopening the country indicates that researchers may return to work soon. As your research teams are preparing to return to their work stations, the safety of patients and staff must be a top priority. Clear policies for how your staff will be conducting their research activities once they are safe to return are needed. The following safety measures can allow the safe reopening of research sites:
Recommendations from the Centers for Disease Control and Prevention
Safe distancing in the workplace is one of the safety policies that have to be in place in the working areas. It will reduce contact between people at their work stations, hence making them safe. Safe distancing will be possible by doing the following:
Changing the Design of the Sites to Allow for Safe Distancing During Monitoring Hours
Your research site should have a new design to minimize close contact during monitoring hours. For instance, you may consider doing the following:
Complete Your Site Initiation Visits
It would be best if you strived to think about how the study start-up activities will continue to progress. It will enable your sponsors to come in and help you finish the following activities quickly.
Ensuring Patients are Safe During Study Visits
Proper sanitation should always be in place within your site, and washing of hands with soap and water should be a norm within site. Some of these other protocols should also be in place:
Changing the Schedule of Your Business
This is an era of “new normal”; hence things will be conducted differently. It would be best if you considered whether the research activities would be taking place remotely or onsite. The following should be considered:
By following the measures mentioned above, the reopening of research sites will be possible, and the research will also be conducted efficiently. It would be interesting to hear what companies like Predictive Oncology (NASDAQ: POAI) are doing to resume full operations after the worst of the pandemic is behind us.
About BioMedWire
BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.
To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)
For more information, please visit https://www.biomedwire.com
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer
BioMedWire (BMW)
San Francisco, California
www.biomedwire.com
415.949.5050 Office
Editor@BioMedWire.com
BioMedWire is part of the InvestorBrandNetwork.
The global market for brain tumor treatments is experiencing significant transformation powered by advances in…
A team of researchers has developed a “cost-effective” and simple blood test with the potential…
Nutriband’s AVERSA technology has the potential to improve the safety profile of transdermal drugs susceptible…
Strategic partnerships embrace opportunities to foster innovation, streamline processes and ultimately improve the lives of…
Adageis provides clinics and medical groups with AI-powered tools to track financial outcomes tied to…
Approximately 65% of patients diagnosed with melanoma are unresponsive to immunotherapy. New research suggests that…